Transformative Therapies for Dry, Intermediate & Late-Stage AMD
Welcome to the 6th Dry AMD and Geographic Atrophy Therapeutics Summit
Defining Novel Targets, Validating Endpoints, and Accelerating First-in-Class Therapeutics for Dry AMD and Geographic Atrophy
With late-phase trials advancing, novel mechanisms emerging, and global regulatory expectations evolving, the dry AMD and GA field is accelerating exponentially. Returning digitally for its sixth year, this summit is the only industry-led forum focused exclusively on the therapeutic development for dry AMD and GA.
Hear from 19+ experts across biotech, investment, and consulting, including leaders from Apellis, Ocugen, Clearside Biomedical, Annexon, and VisgenX, as well as FDA-experienced advisors and global investors - as they showcase how to navigate regulatory complexity, de-risk development decisions, and accelerate novel dry AMD and Geographic atrophy therapies toward clinical and commercial success.
Join us at this exclusive forum to stay ahead of the field with real-time updates on retinal clinical strategy, evolving regulatory expectations, precision ocular delivery innovation, and investment trends shaping the future of dry AMD and geographic atrophy therapeutics.
Download the 2024 Event Guide for More Information On:
- 21+ Expert Speaker Faculty
- Interactive Workshops
- Full access to the 3-day agenda and scientific content breakdown
- and more!

World-Class Speaker Faculty Includes:
Previously Attended Companies:
















Testimonials:
“I’m thrilled to join this panel and contribute to the dialogue around advancing therapies for dry AMD and geographic atrophy. With a background in investing across life sciences and healthcare IT, and deep relationships in venture capital and private equity, I understand what it takes to move promising science into the clinic. This is a critical moment for retinal innovation, and I’m excited to help spotlight the strategies and partnerships that can accelerate progress for patients.”
Jeanne Hecht, CEO & Chairwoman of the Board, Lexitas Pharma Services
2025 Partner:
